Kiniksa Pharmaceuticals (KNSA) Competitors $30.22 +0.45 (+1.51%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$30.22 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, NUVL, and LEGNShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Its Competitors Roivant Sciences Revolution Medicines Verona Pharma BridgeBio Pharma Elanco Animal Health Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Legend Biotech Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment. Does the MarketBeat Community prefer KNSA or ROIV? Kiniksa Pharmaceuticals received 119 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.87% of users gave Roivant Sciences an outperform vote while only 65.30% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17565.30% Underperform Votes9334.70% Roivant SciencesOutperform Votes5678.87% Underperform Votes1521.13% Does the media prefer KNSA or ROIV? In the previous week, Kiniksa Pharmaceuticals had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 28 mentions for Kiniksa Pharmaceuticals and 13 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.71 beat Kiniksa Pharmaceuticals' score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of KNSA or ROIV? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, KNSA or ROIV? Kiniksa Pharmaceuticals has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Do analysts rate KNSA or ROIV? Kiniksa Pharmaceuticals presently has a consensus price target of $38.80, indicating a potential upside of 28.39%. Roivant Sciences has a consensus price target of $17.50, indicating a potential upside of 55.14%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is KNSA or ROIV more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Roivant Sciences' net margin of -119.54%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% Roivant Sciences -119.54%-14.05%-12.81% Which has stronger earnings & valuation, KNSA or ROIV? Roivant Sciences has lower revenue, but higher earnings than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$481.17M4.58$14.08M-$0.25-120.88Roivant Sciences$29.05M263.94$4.35B-$0.25-45.12 SummaryRoivant Sciences beats Kiniksa Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.21B$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-215.848.7827.1220.06Price / Sales4.58255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book4.856.557.064.70Net Income$14.08M$143.93M$3.23B$247.88M7 Day Performance2.37%3.84%2.86%2.63%1 Month Performance12.59%11.20%9.07%6.36%1 Year Performance59.64%4.18%31.45%14.05% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals3.2478 of 5 stars$30.22+1.5%$38.80+28.4%+61.1%$2.21B$481.17M-215.84220Trending NewsInsider TradeROIVRoivant Sciences2.3781 of 5 stars$11.17+1.6%$17.50+56.7%+6.7%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.4448 of 5 stars$40.65+3.2%$67.08+65.0%+4.5%$7.57B$742K-11.32250Positive NewsVRNAVerona Pharma2.3658 of 5 stars$84.10+3.6%$82.13-2.3%+573.5%$6.82B$118.54M-43.8030Trending NewsAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.6239 of 5 stars$35.46+3.5%$57.09+61.0%+42.1%$6.73B$127.42M-12.44400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionELANElanco Animal Health1.1137 of 5 stars$13.440.0%$15.17+12.9%-22.3%$6.67B$4.43B33.599,800Positive NewsGRFSGrifols3.6544 of 5 stars$8.30-0.1%N/A+28.4%$5.71B$7.21B7.0926,300TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.80-1.1%$22.00+31.0%N/A$5.68B$783.21M0.00N/APositive NewsTGTXTG Therapeutics2.9618 of 5 stars$35.75+1.8%$40.80+14.1%+137.3%$5.68B$386.39M-357.46290Positive NewsAnalyst RevisionNUVLNuvalent2.4074 of 5 stars$77.18+3.4%$115.50+49.7%-2.7%$5.54BN/A-22.2440Positive NewsLEGNLegend Biotech3.0745 of 5 stars$29.32+1.3%$76.20+159.9%-17.3%$5.39B$728.30M-30.861,070Trending NewsShort Interest ↑Analyst Revision Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Verona Pharma Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Grifols Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts